Collegium Pharmaceutical/$COLL
1D1W1MYTD1Y5YMAX
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
- Ticker
- $COLL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 423
- Headquarters
- Stoughton, United States
- Website
- www.collegiumpharma.com
COLL Metrics
BasicAdvanced
$894M
19.55
$1.41
0.76
-
Price and volume
Market cap
$894M
Beta
0.76
52-week high
$50.79
52-week low
$25.47
Average daily volume
639K
Financial strength
Current ratio
1.031
Quick ratio
0.703
Long term debt to equity
372.327
Total debt to equity
390.461
Interest coverage (TTM)
2.25%
Profitability
EBITDA (TTM)
405.255
Gross margin (TTM)
89.45%
Net profit margin (TTM)
5.93%
Operating margin (TTM)
21.24%
Effective tax rate (TTM)
38.32%
Revenue per employee (TTM)
$1,910,000
Management effectiveness
Return on assets (TTM)
5.75%
Return on equity (TTM)
17.61%
Valuation
Price to earnings (TTM)
19.546
Price to revenue (TTM)
1.086
Price to book
2.86
Price to tangible book (TTM)
-0.84
Price to free cash flow (TTM)
2.673
Free cash flow yield (TTM)
37.41%
Free cash flow per share (TTM)
10.277
Growth
Revenue change (TTM)
14.31%
Earnings per share change (TTM)
32.73%
3-year revenue growth (CAGR)
14.60%
3-year earnings per share growth (CAGR)
62.22%
10-year earnings per share growth (CAGR)
-6.28%
What the Analysts think about COLL
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
COLL Financial Performance
Revenues and expenses
COLL Earnings Performance
Company profitability
COLL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.